PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | The NEW ENGLAND JOURNAL Of MEDICINE

Authors: Andrea Cercek, M.D., Melissa Lumish, M.D. https://orcid.org/0000-0003-4173-5567, Jenna Sinopoli, N.P., Jill Weiss, B.A., Jinru Shia, M.D., MichelleLamendola-Essel, D.H.Sc., Imane H. El Dika, M.D., and Luis A. Diaz, Jr., M.D.

BACKGROUND

Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is caused by a deficiency in mismatch repair. Because mismatch repair–deficient colorectal cancer is responsive to programmed death 1 (PD-1) blockade in the context of metastatic disease, it was hypothesized that checkpoint blockade could be effective in patients with mismatch repair–deficient, locally advanced rectal cancer.

METHODS

We initiated a prospective phase 2 study in which single-agent dostarlimab, an anti–PD-1 monoclonal antibody, was administered every 3 weeks for 6 months in patients with mismatch repair–deficient stage II or III rectal adenocarcinoma. This treatment was to be followed by standard chemoradiotherapy and surgery. Patients who had a clinical complete response after completion of dostarlimab therapy would proceed without chemoradiotherapy and surgery. The primary end points are sustained clinical complete response 12 months after completion of dostarlimab therapy or pathological complete response after completion of dostarlimab therapy with or without chemoradiotherapy and overall response to neoadjuvant dostarlimab therapy with or without chemoradiotherapy.
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer

RESULTS

A total of 12 patients have completed treatment with dostarlimab and have undergone at least 6 months of follow-up. All 12 patients (100%; 95% confidence interval, 74 to 100) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging, 18F-fluorodeoxyglucose–positron-emission tomography, endoscopic evaluation, digital rectal examination, or biopsy. At the time of this report, no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months). No adverse events of grade 3 or higher have been reported.

CONCLUSIONS

Mismatch repair–deficient, locally advanced rectal cancer was highly sensitive to single-agent PD-1 blockade. Longer follow-up is needed to assess the duration of response. (Funded by the Simon and Eve Colin Foundation and others; ClinicalTrials.gov number, NCT04165772.)
Locally advanced rectal cancer is typically managed with multimodal therapy, including chemotherapy, radiation, and surgery. Current evidence supports a strategy involving the use of neoadjuvant therapy, in which induction chemotherapy with a fluoropyrimidine in combination with oxaliplatin is followed by chemoradiotherapy and then surgery.1-3 This approach results in a pathological complete response in up to a quarter of patients, but it is associated with marked complications and toxic effects — including bowel, urinary, and sexual dysfunction; infertility; and altered quality of life — in a substantial proportion of patients.4-6 In patients undergoing surgery, resection of the rectum is life-altering and often warrants a permanent diverting colostomy.6,7 Owing to the complications of surgery and the high frequency of pathological complete response, interest in organ-sparing nonoperative management is increasing. The use of clinical complete response that is achieved with neoadjuvant treatment as a surrogate for pathological complete response provides patients with a nonoperative option that results in a survival benefit that is similar to that in patients undergoing surgical resection.8-11
Approximately 5 to 10% of rectal adenocarcinomas are mismatch-repair deficient, and these tumors have been shown to respond poorly to standard chemotherapy regimens, including neoadjuvant chemotherapy in locally advanced rectal cancer.12-14 Immune checkpoint blockade alone has been shown to be highly effective as first-line treatment for patients with mismatch repair–deficient metastatic colorectal cancer, as well as for patients with treatment-refractory disease, with objective response rates of 33 to 55%, clinically significant durability of response, and prolonged overall survival.15-17
On the basis of the benefits seen in the context of metastatic disease, we hypothesized that single-agent programmed death 1 (PD-1) blockade alone might be beneficial in mismatch repair–deficient, locally advanced rectal cancer. To test this hypothesis, we initiated a phase 2 study to investigate the overall response and frequency of sustained clinical complete response to neoadjuvant treatment with dostarlimab, a PD-1 inhibitor, in this patient population.

Skip The Scoop | Seek Understanding

Amnesty International Report 2020/21: The state of the world’s human rights

Show Me

100,000 Illegal Immigrants Escaped: Border Patrol Official

Show Me

Biden Says All Adults Will Be Eligible for Vaccine by April 19

Show Me

Texas Bans Vaccine Passports Via Executive Order

Show Me

CNN Admits Crime Wave, Highlights Violence in Democrat-Run Cities

Show Me

REPORT: New York’s Vaccine Passport Has ‘Massive Security Flaws,’ Barely Functional

Show Me

These 5 states have nearly half of nation’s new COVID-19 cases

Show Me

CDC: Soap and Detergent Enough to Reduce Spread of COVID-19 in Most Cases

Show Me

President Biden advances to April 19 the date that all adults will be eligible for COVID vaccination

Show Me

Fairfax: McAuliffe ‘treated me like George Floyd’ after assault claims surfaced

Show Me

Here’s The Far-Left’s Plan To Take Over Every Federal Court Over Republican Objection

Show Me

A third of COVID survivors suffer mental or neurological problems, study reveals

Show Me

Man accused of trying to extort Max Gaetz admits he asked for cash

Show Me

New York Times Writers May Have Deceived Readers in Stories About Project Veritas: Court

Show Me

The Right View with President Donald J Trump and Lara Trump | Banned By YouTube, Facebook & Twitter | Recorded March 30, 2021 | Video: 18 Minutes

Show Me

Federal Judge Alleges Democrats Are Close to Controlling All Major News Outlets

Show Me

Sidney Powell Blasts Dominion Suit as Bid to ‘Save Business’

Show Me

Analysis: The Stated Goals of the Black Lives Matter Impact Report

Show Me

Border Patrol agents arrest Yemeni men who were on the FBI’s Terrorism Watch List

Show Me

California shooting suspect expected to be arraigned from his hospital bed

Show Me

GOP Congressman Says Fauci Needs To Answer For Why His Agency Bypassed Oversight Of Funding To Wuhan Lab

Show Me

Arkansas Governor Vetoes Transgender Youth Treatment Ban

Show Me

Biden’s ‘Sanctuary Country’ Orders Cut Deportations by 50 Percent

Show Me

Ilhan Omar plays pretend with Capitol attacker story

Show Me

Gov. Kemp Makes Powerful Point About Cancel Culture, Unloads on Joe Biden and Stacey Abrams

Show Me

After Losing Georgia Voter Law Argument, BlueAnon Conspiracy Theorists are FREAKING OUT Because Trump “Hid” A Coke That Was Actually Left in Plain Sight.

Show Me

Blue States and Cities Continue To Struggle With Covid | “Minnesota COVID-19 hospitalizations have nearly doubled since late Feb.”

Show Me

Border Patrol arrests previously deported man with second-degree murder conviction

Show Me

FBI Promises To Hunt Down Anyone Who Lies About Taking COVID Vax As Vaccine Passports Loom

Show Me

FEMA to take over mass vaccination site in Pueblo, increase COVID-19 immunizations

Show Me

Despite COVID, many hospitals had a banner year with federal coronavirus bailout cash

Show Me

AstraZeneca’s Covid vaccine ‘may not be suitable for young people’, Prof Lockdown says

Show Me

NYC COVID positivity rate remains steady even as vaccines ramp up

Show Me

Texas COVID Cases, Deaths Plummet After Gov. Abbott Repeals Mask Mandate

Show Me

Twitter Suspends Marjorie Taylor Greene After She Tweets ‘He Is Risen! Happy Easter!’

Show Me

GOP Rep. Greene Introduces Bill to Cut Fauci’s $400,000 Salary to Zero Until He Is Replaced

Show Me

Rep. Marjorie Taylor Greene Says Democrat-Led Effort to Expel Her ‘Will Fail’

Show Me

‘What a coincidence?’ Marjorie Taylor Greene demands Twitter explain ‘error’ in suspending account

Show Me

Coronavirus cases continue to trend upward despite productive vaccination days (LIVE UPDATES)

Show Me

Wisconsin Governor Asks Court to Force Sidney Powell, Trump to Pay Over $100,000 in Legal Fees

Show Me